A61K 47/644
Transferrin
Official title: {Transferrin, e.g. a lactoferrin or ovotransferrin}
A61K47/644 (Transferrin) appears on 108 US grants and 231 published applications in this corpus.
Search patents in A61K- Granted patents
- 108
- Published applications
- 231
- Assignees
- 120
- Inventors
- 372
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 5 |
| 2003 | 0 | 8 |
| 2004 | 3 | 12 |
| 2005 | 0 | 3 |
| 2006 | 3 | 6 |
| 2007 | 4 | 7 |
| 2008 | 1 | 12 |
| 2009 | 0 | 6 |
| 2010 | 2 | 9 |
| 2011 | 6 | 8 |
| 2012 | 4 | 1 |
| 2013 | 3 | 10 |
| 2014 | 3 | 7 |
| 2015 | 5 | 10 |
| 2016 | 5 | 6 |
| 2017 | 9 | 12 |
| 2018 | 8 | 8 |
| 2019 | 5 | 13 |
| 2020 | 5 | 18 |
| 2021 | 7 | 8 |
| 2022 | 4 | 9 |
| 2023 | 7 | 15 |
| 2024 | 5 | 11 |
| 2025 | 6 | 20 |
| 2026 | 2 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Therapeutic use of P75NTR neurotrophin binding protein14 Jul 2026US 12,679,880 B2Levicept LTD
- Nano-delivery system and therapeutic and diagnostic use thereof10 Mar 2026US 12,569,569 B2Nanocarry Therapetics Ltd.
- Cellular targeted label delivery system2 Dec 2025US 12,485,192 B2Cellis AG
- Cytokine conjugates for the treatment of autoimmune diseases5 Aug 2025US 12,377,131 B2Synthorx, Inc.
- Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery22 Jul 2025US 12,364,661 B2The Regents of the University of California
- Peptide Having Affinity for Human Transferrin Receptor24 Sep 2026US 2026/0285942 A1JCR Pharmaceuticals Co., Ltd.
- Isolated targeted delivery system for the treatment of ovarian cancer23 Jul 2026US 2026/0207519 A1
- Affinity-based methods for using transferrin receptor-binding proteins9 Jul 2026US 2026/0191935 A1Denali Therapeutics Inc.
- Nano-delivery system and therapeutic and diagnostic use thereof18 Jun 2026US 2026/0166174 A1Nanocarry Therapeutics Ltd.
- Isolated targeted delivery system for the treatment of glioma2 Apr 2026US 2026/0091119 A1
Most cited
By later US patents
- Compositions and methods for enhanced transepithelial and transendothelial transport or active agents102US 5,254,342 AUniversity of Southern California · 1993
- Modified transferrin fusion proteins44US 7,176,278 B2Biorexis Technology, Inc. · 2007
- Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR40US 8,470,332 B2Bristol-Myers Squibb Company · 2013
- Method of preparing diphtheria immunotoxins39US 5,208,021 ACetus Corporation · 1993
- Receptor-mediated uptake of peptides that bind the human transferrin receptor35US 6,743,893 B2The UAB Research Foundation · 2004